Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2 5Phase EARLY_PHASE1 3Phase 1/2 1Phase 1 1

Status

Recruiting 12Active not recruiting 7Completed 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24venetoclax 23Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23Azacitidine 23Ipilimumab 22Fluorouracil 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × X-Rays × Clear all
NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Thomas Jefferson University

Phase 1/2 Terminated
52 enrolled 31 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡